Immunotherapy plus targeted therapy before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two medicines given before lung cancer surgery: benmelstobart (an immunotherapy that helps your immune system fight cancer) and anlotinib (a targeted therapy that stops blood vessel growth to tumors). The goal is to see if they make the cancer disappear completely by the time of surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your lung cancer must be a type called non-small cell lung cancer that can be removed with surgery and is at a certain stage (stage II to some stage IIIB).
- A biopsy must show a high PD-L1 protein level (50% or more).
- You cannot have had any prior cancer treatment (like chemo, radiation, or targeted therapy) for this lung cancer.
- Your overall health must be good (no serious heart, lung, bleeding, or immune problems) and your organs need to work well as shown by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests whether giving a combination of two targeted drugs (tislelizumab and anlotinib) plus standard chemotherapy before and after surgery can help people with early-stage lung cancer. The goal is to see if this approach can shrink the tumor and lower the chance of the cancer coming back.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.